What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Trump Proposes 15% Global Tariff as Eli Lilly Outperforms Novo Nordisk

Former President Donald Trump has escalated his trade policy rhetoric by proposing a 15% global tariff on imports. This move signals a potential shift toward more aggressive protectionism, raising concerns about global trade volatility and inflationary pressures. Meanwhile, in the pharmaceutical sector, Eli Lilly continues to solidify its leadership in the lucrative obesity drug market. Recent data suggests Eli Lilly is gaining a competitive edge over its primary rival, Novo Nordisk, as market demand for weight-loss treatments surges. Investors are closely monitoring these developments, as the tariff news weighs on broad market indices like the SPY, while Eli Lilly provides a bullish catalyst for the healthcare sector. The combination of macro geopolitical risks and sector-specific growth highlights a complex landscape for global markets.

Trump Proposes 15% Global Tariff as Eli Lilly Outperforms Novo Nordisk

Key Facts

Instruments